Relationship of <em>PPARG</em>, <em>PPARGC1A</em>, and <em>PPARGC1B</em> polymorphisms with susceptibility to hepatocellular carcinoma in an eastern Chinese Han population

Abstract

BackgroundPPARG, PPARGC1A, and PPARGC1B polymorphisms may be implicated in the development of cancer.Participants and methodsIn this study, we selected PPARG rs1801282 C>G and rs3856806 C>T, PPARGC1A rs2970847 C>T, and PPARGC1B rs7732671 G>C and rs17572019 G>A single-nucleotide polymorphisms to explore the relationship between these polymorphisms and hepatocellular carcinoma (HCC) risk. A total of 584 HCC patients and 923 controls were enrolled.ResultsWe found that PPARG rs1801282 C>G polymorphism was correlated with a decreased susceptibility of HCC (CG vs CC, adjusted OR 0.47, 95% CI 0.27–0.82, P=0.007; CG/GG vs CC, adjusted OR 0.52, 95% CI 0.31–0.88, P=0.015). However, PPARG rs3856806 C>T polymorphism was a risk factor for HCC (TT vs CC, adjusted OR 2.33, 95% CI 1.25–4.36, P=0.008; TT vs CT/CC, adjusted OR 2.26, 95% CI 1.22–4.17, P=0.010). In a subgroup analysis by chronic hepatitis B virus (HBV)-infection status, age, sex, alcohol use, and smoking status, a significant association between PPARG rs1801282 C>G polymorphism and a decreased risk of HCC in male, ≥53 years, never-smoking, never-drinking, and nonchronic HBV-infection-status subgroups was found. However, we found PPARG rs3856806 C>T polymorphism increased the risk of HCC in never-smoking, never-drinking, and nonchronic HBV-infection-status subgroups. Haplotype-comparison analysis indicated that Crs1801282Trs3856806Crs2970847Grs7732671Grs17572019, Crs1801282Trs3856806Trs2970847Grs7732671Grs17572019, and Crs1801282Crs3856806Crs2970847Crs7732671Ars17572019 haplotypes increased the risk of HCC. PPARG Crs1801282Trs3856806 and Grs1801282Crs3856806 haplotypes also influenced the risk of HCC.ConclusionIn conclusion, our findings suggest PPARG polymorphisms may influence the susceptibility of HCC. The PPARG, PPARGC1A, and PPARGC1B haplotypes might be associated with HCC risk.

Illumination of Molecular Pathways in Multiple Sclerosis Lesions and the Immune Mechanism of Matrine Treatment in EAE, a Mouse Model of MS

“…ANXA1 was also considered as a primary endogenous mediator of the anti-inflammatory and immunosuppressive actions of gluco-corticoids (57). Peroxisome proliferator activated receptor gamma (PPARG) encoded a protein called PPARg, which regulates adipocyte differentiation and has been implicated in the pathology of many diseases, including obesity, diabetes, atherosclerosis and cancer (58)(59)(60). Ursolic acid has been reported to play an anti-inflammatory and neurorepair role by upregulating myelin-related gene expression through PPARg activation (61).…”

Exploration and Verification of a Six-RNA&nbsp;Binding Proteins-based Prognosis Evaluating Model for Hepatocellular Carcinoma

“…There were six RBPs highlighted as core genes, including UPF3B, MRPL54, ZC3H13, DHX58, PPARGC1A and EIF2AK4. Previous study has demonstrated that ZC3H13 was associated with OS of LIHC patients [32] and PPARGC1A was related to people's susceptibility of HCC [33], however the roles of the others in HCC are yet to be con rmed. Hereafter, these six RBPs together with their coe cient returned by multi-step COX regression were enrolled into our risk model, which was trained in TCGA datasets.…”

A Novel RNA Binding Protein-Related Prognostic Signature for Hepatocellular Carcinoma

“…In addition, Zhang et al. observed that PPARGC1A rs2970847 C>T polymorphisms associated with HCC risk ( 54 ). Given the importance of the six RBP genes in kinds of cancer types, these genes might be potential prognostic biomarkers for patients with HCC, but detailed molecular mechanism during hepatocarcinogenesis needs further in-depth exploration.…”